In 2014, one of the largest outbreaks of Ebola virus occurred in West Africa. Following this outbreak, there has been a dramatic push for developing and improving therapies for emerging viruses. While research has led to trial vaccines, we still have limited options for treatments. Viruses are not alive and must depend on the host they infect to complete their lifecycle. Thus, one approach to developing antiviral treatments is understanding how the virus interacts with host cells so we can identify potential targets for intervention. I will be sharing my path to pursuing my PhD and my current research on the role of viral-human interactions that impact Ebola and Marburgvirus replication. It takes a large team to combat the threat emerging viruses pose to public health. I hope to showcase one avenue you can pursue to be a part of the solution.

Background: Veronica is a PhD candidate at Purdue University where she conducts her research in Dr. Doug LaCount’s lab. Their group studies human-viral interactions necessary for viral replication of emerging viruses. Before coming to Purdue, Veronica earned her B.S. in biology from Southern Illinois University Edwardsville.